Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026

Same author

Engineering potent TILs from an immune-excluded tumor: Insights from chondrosarcoma.

Molecular therapy. Oncology·2026

Same author

Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.

Frontiers in oncology·2026

Same author

A Predictive MRI Radiomics Model for Histologic Differentiation in Soft Tissue Sarcomas.

Cancers·2026

Same author

BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCER.

Cancer discovery·2026

Same author

Performance of deep learning-based segmentation of soft tissue sarcoma by MRI sequence, tumor type and location.

Skeletal radiology·2026

Search research articles

Related Experiment Video

Updated: Mar 19, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Revisiting the Immune Frontier in Soft Tissue Sarcomas.

Nadeem Bilani¹, Nourhane Al Akoum¹, Rusul Al-Marayaty²

¹Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.

Current Oncology Reports

|March 17, 2026

Summary

Immuno-oncology shows promise for soft tissue sarcomas (STS). Combination therapies and engineered T-cell treatments are improving outcomes for advanced STS, moving beyond modest results from immune checkpoint inhibitors alone.

Keywords:

Forward-looking perspective Histology-specific responses Immuno-oncology Immunotherapeutic strategies Outcomes Phase I–III clinical trials Soft tissue sarcoma (STS)Trial design and therapeutic development

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: Mar 19, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Area of Science:

Oncology
Immunotherapy
Soft Tissue Sarcomas

Background:

Soft tissue sarcomas (STS) are a diverse group of cancers with limited advanced treatment options.
Immune checkpoint inhibitors (ICIs) have shown modest, histology-dependent efficacy in STS.
This review synthesizes recent immuno-oncology advances in STS.

Purpose of the Study:

To review current immuno-oncology strategies for soft tissue sarcomas.
To highlight emerging approaches for overcoming resistance to immunotherapy in STS.
To discuss potential improvements in patient outcomes.

Main Methods:

Literature review of recent advances in immuno-oncology for STS.
Analysis of clinical trial data for combination therapies and cellular therapies.
Examination of tumor microenvironment factors influencing immunotherapy response.

Main Results:

Clinically significant activity of ICIs observed in specific STS subtypes (e.g., undifferentiated pleomorphic sarcoma, angiosarcoma).
Combination therapies (ICI + chemo/radiation/TKIs/immune modulators) demonstrate enhanced antitumor activity.
Engineered T-cell therapies are a standard for synovial sarcoma and expanding to other histologies.
Tumor microenvironment characterization aids patient selection and trial design.

Conclusions:

Immunotherapy is transforming STS treatment, but ICI monotherapy benefits a subset.
Rational combination strategies and cellular therapies offer broader efficacy.
Biomarker-driven, histology-specific trials are crucial for realizing immunotherapy's full potential in STS.